NASDAQ:INSM Insmed (INSM) Stock Price, News & Analysis $119.80 -2.06 (-1.69%) Closing price 11/18/2026 04:00 PM EasternExtended Trading$121.50 +1.70 (+1.41%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Insmed Stock (NASDAQ:INSM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Insmed alerts:Sign Up Key Stats Today's Range$118.83▼$122.4250-Day Range$93.33▼$129.4152-Week Range$90.39▼$212.75Volume1.94 million shsAverage Volume3.74 million shsMarket Capitalization$26.28 billionP/E RatioN/ADividend YieldN/APrice Target$196.52Consensus RatingModerate Buy Company Overview Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis. Insmed also develops investigational medicines for respiratory and other serious conditions. Insmed serves patients in the United States and select international markets. The company traces its origins to 1988 and has evolved from a specialty pharmaceutical business into a biotechnology company focused on developing therapies for conditions with limited treatment options.AI Generated. May Contain Errors. Read More Insmed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreINSM MarketRank™: 3.007534246575 of 5 starsInsmed scored higher than 60% of companies evaluated by MarketBeat, and ranked 579th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingInsmed has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 1 strong buy rating, 23 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialInsmed has a consensus price target of $196.52, representing about 64.0% upside from its current price of $119.80.Amount of Analyst CoverageInsmed has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Insmed's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Insmed are expected to grow in the coming year, from ($1.86) to $0.62 per share.Price to Book Value per Share RatioInsmed has a P/B Ratio of 36.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.56% of the float of Insmed has been sold short.Short Interest Ratio / Days to CoverInsmed has a short interest ratio ("days to cover") of 3.56, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Insmed has recently increased by 4.47%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInsmed does not currently pay a dividend.Dividend GrowthInsmed does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.61 News SentimentInsmed has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Insmed this week, compared to 9 articles on an average week.Search InterestOnly 12 people have searched for INSM on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Insmed to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Insmed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,100,000.00 in company stock.Percentage Held by Insiders2.10% of the stock of Insmed is held by insiders.Percentage Held by InstitutionsInsmed has minimal institutional ownership at this time.Read more about Insmed's insider trading history. Receive INSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INSM Stock News HeadlinesInsmed Incorporated (INSM) Presents at Jefferies Global Healthcare Conference 2026 TranscriptNovember 16 at 9:24 PM | seekingalpha.comContrasting Insmed (NASDAQ:INSM) and Applied Therapeutics (NASDAQ:APLT)November 16 at 2:31 AM | americanbankingnews.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks. | Weiss Ratings (Ad)Insmed, Inc. (NASDAQ:INSM) Stock Has Average Target Price of $196.52November 14, 2026 | americanbankingnews.comThe Zacks Analyst Blog Highlights TG Therapeutics, BioCryst, Insmed and MadrigalNovember 11, 2026 | finance.yahoo.comInsmed: A Blockbuster Launch, Priced Ahead Of Its Own GuidanceNovember 7, 2026 | seekingalpha.comInsmed to Present at November and December 2026 Investor ConferencesNovember 4, 2026 | prnewswire.comMizuho Adjusts Price Target on Insmed to $158 From $154, Keeps Outperform RatingNovember 2, 2026 | marketscreener.comMSee More Headlines INSM Stock Analysis - Frequently Asked Questions How have INSM shares performed this year? Insmed's stock was trading at $174.04 at the beginning of the year. Since then, INSM stock has decreased by 31.2% and is now trading at $119.80. How were Insmed's earnings last quarter? Insmed, Inc. (NASDAQ:INSM) issued its earnings results on Thursday, October, 29th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.38) by $0.08. The business's revenue was up 268.4% compared to the same quarter last year. Read the conference call transcript. Who are Insmed's major shareholders? Insmed's top institutional shareholders include State Street Corp (2.81%), Pictet Asset Management Holding SA (0.80%), Bellevue Group AG (0.69%) and Assenagon Asset Management S.A. (0.58%). Insiders that own company stock include Melvin Md Sharoky, William Lewis, John Drayton Wise, Roger Adsett, David W J Mcgirr, Martina MD Flammer, Sara Bonstein, Elizabeth M Anderson, Leo Lee, Orlov S Nicole Schaeffer, David R Brennan, Michael Alexander Smith, Clarissa Desjardins and Clarissa Desjardins. View institutional ownership trends. How do I buy shares of Insmed? Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Insmed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Insmed investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Tesla (TSLA), Palantir Technologies (PLTR), Broadcom (AVGO) and Intel (INTC). Company Calendar Last Earnings10/29/2026Today11/19/20269th Annual Evercore ISI HealthCONx Conference12/01/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, INSM's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:INSM CIK1104506 Webwww.insmed.com Phone908-977-9900Fax732-438-0381Employees1,664Year FoundedN/APrice Target and Rating Average Price Target for Insmed$196.52 High Price Target$263.00 Low Price Target$154.00 Potential Upside/Downside+64.0%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage26 Analysts Profitability EPS (Trailing Twelve Months)($2.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.28 billion Net Margins-39.85% Pretax Margin-39.35% Return on Equity-96.38% Return on Assets-32.55% Debt Debt-to-Equity Ratio0.77 Current Ratio2.86 Quick Ratio2.59 Sales & Book Value Annual Sales$606.42 million Price / Sales43.34 Cash FlowN/A Price / Cash FlowN/A Book Value$3.31 per share Price / Book36.19Miscellaneous Outstanding Shares219,380,000Free Float214,773,000Market Cap$26.28 billion OptionableOptionable Beta0.83 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:INSM) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public co...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Insmed With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.